| name | pediatric-obesity-intervention-selector |
| description | Select the right treatment tier for a child with obesity — behavioural, pharmacologic, or surgical — using the CMAJ 2025 pediatric obesity guideline. Trigger when a clinician asks what to do for a child with obesity, which intervention to start, whether to escalate treatment, or when to consider medication or surgery for pediatric obesity. |
Pediatric Obesity: Intervention Selector
Step-by-step guide to selecting the appropriate intervention tier for a child (0–18 years) with obesity. Based on CMAJ 2025 Clinical Practice Guideline (Ball et al., doi: 10.1503/cmaj.241456).
Step 1 — Gather Key Information
Before recommending anything, confirm:
- Age (years)
- BMI z-score (BMIz) using WHO growth charts for Canada
- What has already been tried (duration, adherence, response)
- Comorbidities (metabolic, mechanical, mental health — see 4Ms below)
- Family preferences and values — what outcomes matter most to them?
- Social determinants (food security, neighbourhood, family dynamics)
⚠️ Use person-first, neutral language throughout. Say "child with obesity" not "obese child." Refer to BMI, weight, or growth — not "fat" or "overweight."
Step 2 — First-Line: Behavioural & Psychological Interventions
All children with obesity, regardless of age.
Strong recommendation, very low to moderate certainty.
Recommend a multicomponent intervention — must include at least 2 of:
- Physical activity
- Nutrition counselling
- Psychological support (e.g., CBT, motivational interviewing)
- Technology-assisted components (optional; weak evidence)
Individual components alone (nutrition-only, exercise-only) are conditional recommendations with weaker evidence — prefer multicomponent.
Practical targets:
- Higher-intensity sessions (aerobic + resistance training) superior to low-intensity
- Goal-setting, self-monitoring, problem-solving, and relapse prevention are effective behaviour change tools
- At least 26 hours of contact time improves outcomes
- Long-term support is essential — obesity is chronic and relapsing
Technology interventions alone: Neither for nor against (insufficient evidence).
Step 3 — Escalate to Pharmacotherapy?
Consider if: inadequate response to behavioural/psychological interventions AND age ≥ 12 years.
⚠️ No stepwise requirement — pharmacotherapy can be offered alongside, not only after, behavioural therapy. It must always be combined with behavioural/psychological interventions.
→ Go to the Pharmacotherapy Selector skill for agent selection.
If age < 12: insufficient evidence for any pharmacotherapy — do not prescribe.
Step 4 — Escalate to Surgery?
Consider if: age ≥ 13 years AND deemed eligible after comprehensive multidisciplinary assessment.
⚠️ Surgery does not require prior failure of pharmacotherapy. Consider based on severity, comorbidities, family preference, and centre availability.
Surgical options: Laparoscopic sleeve gastrectomy (LSG) or Roux-en-Y gastric bypass (RYGB). Both: conditional recommendation, low to moderate certainty.
Requirements before referral:
- Specialized, multidisciplinary team assessment
- Psychological/psychiatric clearance
- Nutritional assessment
- Family/caregiver involvement and support
- Shared decision-making about serious AE risk
→ Go to the Surgical Eligibility Screener skill for full checklist.
Step 5 — Shared Decision-Making at Every Tier
At every tier, the conversation matters as much as the prescription:
- Present all options (behavioural, pharmacologic, surgical) — no option should be withheld from discussion
- Acknowledge the balance of benefits and harms for each option
- Align on what success looks like — HRQoL, mood, mobility, not just BMI
- Involve both child and caregiver in the decision (separately if helpful)
- Address social determinants that may affect access or adherence
- Refer to multidisciplinary team where available
Clinical Guardrails
- Eating disorder vigilance: Ask about binge eating, body image concerns, atypical anorexia — especially before pharmacotherapy or surgery. Refer to specialist if suspected.
- Don't focus solely on weight. Improved HRQoL, depression, anxiety, and cardiometabolic markers are equally valid outcomes.
- Obesity is not a personal failing. Genetics, physiology, and environment drive it. Frame this clearly for families.
- Lipase inhibitors (orlistat): Suggested but not preferred — higher GI side effects and serious AE risk. Use only if GLP-1RA and metformin unavailable.
- Technology-only interventions: Insufficient evidence — do not use as a standalone strategy.
Source
CMAJ 2025 Clinical Practice Guideline: Managing obesity in children.
Ball GDC et al. CMAJ 2025 April 14; 197:E372–89. doi: 10.1503/cmaj.241456
Updated version: June 3, 2025.
